Literature DB >> 35925359

[Diagnostics and treatment of ocular toxoplasmosis : Results of a survey].

A Taghavi-Eraghi1, J G Garweg2, U Pleyer3.   

Abstract

BACKGROUND: Ocular toxoplasmosis (OT) is the most common infectious cause of posterior uveitis. This survey aimed to evaluate the current diagnostic and therapeutic approach to OT in Germany.
MATERIAL AND METHODS: A detailed questionnaire with specific patient examples was sent in July 2021 to the members of the Uveitis Section of the German Ophthalmological Society (DOG) and the Retinological Society (RG).
RESULTS: The questionnaire was answered by 53 (29 RG and 24 DOG) ophthalmologists. Of the respondents 16 (30%) work in private practice, 18 (34%) in a clinical facility and 19 (36%) in university hospital, 9 (17%) colleagues see < 50, 28 (53%) 50-200 and 16 (30%) more than 200 uveitis patients per year. The clinical results are still the gold standard (87%) for the diagnosis of OT and in cases of first manifestation 60% are supported by serological antibody investigations, while 10 out of 53 (19%) ophthalmologists rely on the clinical presentation only. An IgM test is requested by 25 (47%) respondents, 6 expected an increase in IgG titer (11%) and 1 the detection of specific IgA antibodies (2%). The majority (n = 28, 53%) of ophthalmologists would aim at confirming the diagnosis by an anterior chamber puncture, from which 20 (38%) prefer PCR, 3 (6%) determination of Goldmann-Witmer coefficients (GW) and 5 (9%) a combination of both methods. Clindamycin was most frequently used for treatment (n = 21, 40%), followed by pyrimethamine/sulfadiazine (n = 17, 32%) and trimethoprime + sulfamethoxazole (TMP/SMX) (n = 10, 19%); the latter was also used (n = 40, 75%) for secondary prophylaxis.
CONCLUSION: The results show that apart from the clinical results as the gold standard for the diagnosis, there is no uniform approach to diagnosis and treatment of OT. The high request rate for serum IgM antibodies indicates a widespread uncertainty about the importance of serological findings. This should be viewed critically, given the continued high seroprevalence in Germany.
© 2022. The Author(s).

Entities:  

Keywords:  Antibody investigations; Combination treatment; Secondary prophylaxis; Serology; Uveitis

Year:  2022        PMID: 35925359     DOI: 10.1007/s00347-022-01691-7

Source DB:  PubMed          Journal:  Ophthalmologie        ISSN: 2731-720X


  2 in total

Review 1.  Toxoplasmosis in Germany.

Authors:  Uwe Pleyer; Uwe Gross; Dirk Schlüter; Henrik Wilking; Frank Seeber
Journal:  Dtsch Arztebl Int       Date:  2019-06-21       Impact factor: 5.594

2.  Current practice in the management of ocular toxoplasmosis.

Authors:  Kengadhevi Yogeswaran; João M Furtado; Bahram Bodaghi; Janet M Matthews; Justine R Smith
Journal:  Br J Ophthalmol       Date:  2022-02-23       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.